1王合兵.Her-2过表达与乳腺癌治疗的研究进展[J].肿瘤学杂志,2008,14(2):151-153.
2Vogel CL,Cobleigh MA,Tripathy D,et al.First-line herceptin monotherapy in me-tastatic breast cancer[J].Oncology,2001,61(Suppl2):37-42.
3Fornier M,Esteva FJ,Seidman AD.Trastuzumab in combination with chemothera-py for the treatment of metastatic breast cancer[J].Semin-Oncol,2000,27:38-45.
4Slamon DJ,Leyland-Jones B,Fuchs H,et al.Use of chemotherapy plus a mono-clonal antibody against Her-2for metastatic breast cancer that overexpresses Her-2[J].N Engl J Med,2001,344(11):783-792.
5GralowJR.Optimizing the treatment of metastatic breast cancer[J].Breast Canc-er Res Treat,2005,89(Suppl1):S9-S15.
6Pegram MD,Lopez A,Konecny G,et al.Trastuzumab and chemotherapeutics:drug interactions and synergies[J].Semin Oncol,2000,27(suppl11):21-25.
7Slamon DJ,Leyland-Jones B,Fuchs H,et al.Use of chemotherapy plus a mono-clonal antibody against Her-2for metastatic breast cancer that overexpresses Her-2[J].N Engl J Med,2001,344(11):783-792.
8Burstein HJ,Kuter I,Campos SM,et al.Clinical activity of trastuzumab and vi-norelbine in women with Her-2-overexpressing metastatic breast cancer[J].J Clin Oncol,2001,19(10):2722-2730.
9Domenech GH,Vogel CL.Areviewof vinorelbine in the treatment of breast cancer[J].Clin Breast Cancer,2001,2(2):113-128.
10Vogel CL,Cobleigh MA,Tripathy D,et al.Efficacy and safety of trastuzumab as a single agentin first-line treatmentof Her-2overexpressingmetastatic breastcanc-er[J].J Clin Oncol,2002,20(3):719-726. |